Valerian Valerenic Acid 0.8.

Melatonin acts on MT1 and MT2 receptors and shifts the timing of the sleep signal, while valerenic acid interacts with the GABA-A receptor complex. Because the targets differ, the two are commonly combined so one addresses timing and the other addresses sedation. Additive sedation is the practical caution, particularly alongside anything else that reduces alertness.

Theanine is a glutamate analogue with documented effects on subjective calm and on alpha-band EEG activity. Valerian acts at a different site on the same inhibitory system. Combining them can compound drowsiness, which matters for driving and for anyone already taking something sedating.

Passionflower and valerian appear together in the same night-time preparations across most European pharmacopoeial traditions. In vitro work places constituents of both at the GABA-A receptor, though at different subunit interfaces. The additive sedative effect is the reason for the pairing and also the reason to keep total dose in view.

Lemon balm constituents inhibit GABA transaminase in vitro, which would slow the breakdown of GABA, while valerenic acid works on the receptor side. Two points on one pathway is the rationale for the classic valerian and lemon balm combination. In vitro pathway logic is weaker evidence than a trial of the pair.

Chamomile carries apigenin, which binds the benzodiazepine site of the GABA-A receptor in binding assays. Valerenic acid modulates the same receptor complex at the beta subunit. Two modulators of one receptor is an additive-sedation setup and should be dosed as one combined effect.

Apigenin is a documented ligand at the benzodiazepine binding site of the GABA-A receptor, which is a well characterised in vitro finding. Valerenic acid modulates the same receptor through beta2 and beta3 subunits. Isolated apigenin plus a standardised valerian extract therefore stack on one target rather than two.

Valerenic acid is a positive modulator, meaning it changes how the receptor responds to GABA rather than opening the channel by itself. Supplemental GABA has limited central-nervous-system entry in adults, so most of its reported effects are debated and peripheral. The mechanistic relationship is clear even where the supplement pairing is not.

Magnesium sits in the NMDA receptor pore as a voltage-dependent blocker, damping excitatory signalling, and glycine is itself an inhibitory neurotransmitter at spinal and brainstem receptors. Valerian works on the GABA side of the same inhibitory and excitatory balance. The result is more inhibition from two directions, which is why the pair is common in night formulas.

Glycine acts as an inhibitory neurotransmitter through its own strychnine-sensitive receptor and also lowers core body temperature at gram doses, which is relevant to sleep onset. Valerian's target is separate. The two together increase total inhibitory load.

Pyridoxal 5-phosphate is the obligatory cofactor for glutamate decarboxylase, the enzyme that makes GABA from glutamate. Without adequate B6 in its active form, GABA synthesis is limited no matter what happens at the receptor. Valerenic acid only modulates a receptor that GABA has to reach, so cofactor sufficiency is upstream of the whole mechanism.

Tryptophan is the dietary precursor for serotonin and then melatonin, a synthesis route that is rate-limited by tryptophan hydroxylase. That is a different pathway from GABA-A modulation. Stacking them adds a precursor arm to a receptor arm, and also adds sedation.

5-HTP is decarboxylated directly to serotonin, skipping the rate-limiting hydroxylation step. Combined with valerian it adds serotonergic load to a GABAergic effect. Caution belongs on the serotonergic side rather than on the valerian side.

Honokiol and magnolol are described as GABA-A modulators in receptor assays. Pairing them with valerian puts two plant modulators on one receptor complex. Additive drowsiness is the expected consequence and should be treated as one total dose.

Ashwagandha is studied mainly on cortisol and on subjective stress rather than on receptor-level sedation. Valerian acts at the receptor. They appear together because the formulation goal overlaps, not because the mechanisms do.

Valerian and hops are the oldest standing combination in this category and are dosed together in most European monograph products. Hop bitter acids are lipophilic and are carried in the same ethanol-water extract as valerenic acid, so one extraction step handles both. The clinical work on the combination is mostly on the fixed pair rather than on hops alone.

Caffeine is an adenosine receptor antagonist and blocks the accumulating sleep-pressure signal, which works against anything taken to reduce alertness. Its half-life in adults runs several hours, so an afternoon dose is still circulating at bedtime. Taking both is a direct pharmacological conflict rather than a synergy.

St John's wort induces CYP3A4 and intestinal P-glycoprotein through the pregnane X receptor, which lowers systemic exposure to many co-taken compounds cleared by those routes. That induction is one of the most consistently documented herb interactions in pharmacology. The relevant caution is what else a person is taking, not the valerian itself.

A whole-root powder and a standardised valerenic acid extract are the same plant at different concentrations, so taking both stacks one active. Root powder delivers the full constituent mix at low valerenic acid density; the standardised extract concentrates the lipophilic fraction. Count them as one total when they appear in the same regimen.